Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Rimegepant (Nurtec ODT) is indicated for the acute treatment of migraine with or without aura in adults, as well as for the treatment of episodic migraine in adults.
• A total of 14 studies were reviewed to gather insights on rimegepant's efficacy and safety profile compared to other treatments such as lasmiditan, ubrogepant, zavegepant, and various triptans.
• The studies showed that rimegepant has a favorable efficacy profile for achieving pain relief within 2 hours when compared to ubrogepant (25 mg and 50 mg) and zavegepant. It also demonstrates a higher probability of achieving freedom from photophobia within 2 hours compared to ubrogepant (25 mg) and lasmiditan (50 mg).
• In direct comparisons with triptans, rimegepant was generally found less effective regarding pain freedom at two hours but had a better safety profile than most triptans.
• Rimegepant displays a relatively favorable safety profile; its risk level concerning adverse events is comparable to placebo. However, it poses slightly higher risks than placebo but lower incidences than triptans regarding primary outcomes like any adverse events or treatment-related ones.
• Specific adverse drug reactions associated with rimegepant correlated with sociodemographic factors including dosage effects on muscle strain & liver function along with Body Mass Index (BMI).
• Studies included predominantly female participants, reflecting the high prevalence rate among women. Significant correlations were found between specific side-effect incidence rates & clinical characteristics (e.g., age), suggesting certain subgroups may be more susceptible to these effects.
• The impact of sociodemographic factors on drug efficacy & tolerability indicates the importance of personalized approaches considering individual patient history, risk factors, and potentiality for adverse events.